Crohn’s Disease

Am I eligible for this study?

To find out, please answer yes or no to the following questions.

 
 
Yes
 
No
1

Are you 18 to 75 years of age?

 
2

Have you been diagnosed with Crohn's disease?

 

Overview

If you are diagnosed with Crohn’s disease, you may qualify for a research study of an investigational medication.

You may qualify to participate in this study if you:

  • Are 18 to 75 years of age
  • Currently have moderate to severe active Crohn’s disease
  • Have been diagnosed with Crohn’s disease for at least 6 months
  • Additional criteria applies

Qualified participants may receive study-related care and medcation or placebo at no cost, and may be reimbursed for study-related travel.

Age
Gender
Condition
18 to 75 years of age
Male and Female
Crohn's Disease

Why take part?

Participants will receive study-related doctor’s care, study medication at no cost. Compensation for study-related time and travel may be available. Millions of people lack the treatment they need to manage their conditions. As one of the largest and most recognized clinical study organisations in the world, Synexus provides a friendly relaxed environment where you have the opportunity to help others and maybe also yourself.

Who is Synexus?

Synexus is a company dedicated to conducting clinical studies, and has been investigating the effectiveness of new study drugs and treatments for more than 20 years. We provide a friendly, relaxed environment in our own clinics where you have the chance to help shape the future of health for yourself and for others.We are sure you probably have more questions about the study, and we would be happy to take the time to give you more details.

All Synexus studies are approved by an independent ethics committee.

Recruiting at the following locations

 
Location
Location
 
Wasatch Peak Family Practice Quick view

Still unsure?

Feel free to call us on to find out more about this study.

 

Your feedback is vital to the success of our research. Please fill in the form fields below.